ClinicalTrials.gg
RecruitingNCT06601140EMC1Updated Feb 19, 2026

Evaluation of the Concordance Between Measures Obtained by a Medical Device for Emotional Monitoring (EMOCARE) and the Patient Health Questionnaire (PHQ-9) Score in Patients With Mild to Severe Depressive Episode

An interventional study of EMOCARE software in Major Depressive Disorder (MDD), sponsored by Emobot. Recruiting at 11 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Emobot · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 127 studies in Depressive Disorder, Major with a site in France — 28 open to participants now, 31 under way, 2 of them phase 3. Depressive Disorder, Major · France.

Planned enrollment
73rd of 106
104 · median 232
Started
2025
with 9 others
No phase
50 of 127
19 open now
Primary completion
2027-02
later than 13 of 30 live
Registered
109th of 127
by date

Among the 127 studies in Depressive Disorder, Major with a site in France, this one is the 73rd largest by planned enrollment of the 106 interventional ones that give a count, is one of 10 that started in 2025, is one of 50 with no phase, reaches primary completion later than 13 of the 30 other live ones, and was the 109th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

28 of the 127 studies in Depressive Disorder, Major with a site in France are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Depressive Disorder, Major with a site in France, or all of them as a file.
02

Study summary

The aim of this clinical investigation is to find out whether the EMOCARE emotional monitoring software provides consistent results compared with the tools available for assessing the emotional state of patients suffering from mild to moderately severe depressive episod. It will also provide information on how patients feel about the use of passive monitoring software (without the active involvement of patient). The main questions it aims to answer are as follows:

Does EMOCARE provide consistent results compared with tools already used in current practice? What are the medical problems encountered by participants when using EMOCARE?

The researchers will compare EMCOCARE to various questionnaires usually used in the management of patients suffering from depression (PHQ-9, MADRS, GAD-7, BDI-II, EQ-5D-5L).

Participants who agree to take part in the study, during a selection visit, will be able to:

  1. Install the software on a digital interface (smartphone, computer, etc.) and activate or deactivate it whenever they wish during the 6-week follow-up period.
  2. Attend 2 scheduled appointments at the centre (a first appointment then a second 6 weeks later) to complete a series of questionnaires, being questioned by the doctor, and fill in other questionnaires on their own.
  3. At home, answer questionnaires independently, 2 weeks and 4 weeks after the first appointment.
  4. Receive a telephone call from the doctor 3 weeks after the first appointment to find out how the participants are feeling.
  5. Keep a diary with the symptoms they have experienced, any medical consultations they have made, or changes in drug treatment.
03

Conditions studied

  • Major Depressive Disorder (MDD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient of both sexes aged 18 or over.
  • Outpatient with unipolar depression (regardless of the time of the episode) (major depressive disorder).
  • Patient with an episode of major depression supported by PHQ-9 score greater than or equal to 5.
  • Patient with an episode of major depression supported by MADRS score greater than or equal to 7.
  • Patient accustomed to regular use of a smartphone and/or computer
  • Patient who, in the opinion of the investigator, will comply with the requirements of the protocol.
  • Patient affiliated to a social security scheme or beneficiary of such a scheme.
  • Patient who has received full information about how the clinical investigation shall be conducted and has signed an form.
  • Patient who reads and understands French.
  • Patient who has undergone clinical screening adapted to the clinical investigation.

Exclusion criteria

Exclusion Criteria:

  • Patient treated with antipsychotic drugs.
  • Patient with an unstable pathology that could interfere with the study.
  • Patient unable to communicate or cooperate with the investigator due to a low mental level, language difficulties or impaired cerebral function.
  • Patient with an active suicidal tendency or patient who has had a suicidal episode in the last 6 months
  • Patients with borderline personality disorders.
  • Patient with a to the product(s) under evaluation.
  • Woman of childbearing age without effective .
  • Pregnant woman, birthing or breastfeeding mother
  • Minor (not emancipated)
  • Incapacitated person
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    EMOCARE

    Device: EMOCARE software

Interventions

  • DeviceEMOCARE software

    Use of the EMOCARE software on the digital device of participant (smartphone, computer, etc.). The participant can activate and deactivate the software whenever he wishes.

06

What researchers measure

Primary outcomes

  1. Change of scores EMOCARE

    Absolute difference

    Time frame: From baseline to 6 weeks

  2. Change of scores PHQ-9 self-administrered

    Absolute difference

    Time frame: From baseline to 6 weeks

Secondary outcomes

  1. Score EMOCARE

    Time frame: At baseline, at 2 weeks, at 4 weeks

  2. Change of EMOCARE score

    Time frame: From baseline to 2 weeks, from baseline to 4 weeks

  3. Score PHQ-9 self administered

    Time frame: At baseline, at 2 weeks, at 4 weeks, at 6 weeks

  4. Change of score PHQ-9 self administered

    Time frame: From baseline to 2 weeks, From baseline to 4 weeks

  5. Score PHQ-9 administered by an investigator

    Time frame: At baseline, at 6 weeks

  6. Change of score PHQ-9 administered by an investigator

    Time frame: From baseline to 6 weeks

  7. Score MADRS administered by an investigator

    Time frame: At baseline, at 6 weeks

  8. Change of MADRS administered by an investigator

    Time frame: From baseline to 6 weeks

  9. Score BDI-II

    Time frame: At baseline, at 6 weeks

  10. Change of BDI-II

    Time frame: From baseline to 6 weeks

  11. Score BDI-II

    Time frame: At baseline, at 2 weeks, at 4 weeks, at 6 weeks

  12. Change of BDI-II

    Time frame: From baseline to 2 weeks, from baseline to 4 weeks, from baseline to 6 weeks

  13. EMOCARE operating time

    Time frame: From baseline to 2 weeks, from baseline to 4 weeks, from baseline to 6 weeks

  14. EQ-5D-5L

    Time frame: At baseline, at 6 weeks

  15. Number of patient with adverse event

    Time frame: At baseline, at 2 weeks, at 3 weeks, at 4 weeks, at 6 weeks

  16. Acceptability of medical device questionnaire

    Time frame: At baseline, at 6 weeks

07

Study locations

6 of 11 sites recruiting
  • Private psychiatric practice
    Agen, 47000, France
    Recruiting
  • Private psychiatric pratice
    Caen, 14000, France
    Recruiting
  • Centre Psychothérapique de Nancy
    Laxou, 54521, France
    Not yet recruiting
    • Raymund SCHWAN, Professor · Principal investigator
  • Private psychiatric practice
    Maxéville, 54320, France
    Terminated

    Not enrolling at this site.

  • Private psychiatric practice
    Nantes, 44000, France
    Recruiting
  • Centre Hospitalier Universitaire de Nantes
    Nantes, 44093, France
    Not yet recruiting
  • Private psychiatric practice
    Paris, 75013, France
    Not yet recruiting
  • Private psychiatric practice
    Reims, 51000, France
    Not yet recruiting
  • Centre hospitalier Guillaume Régnier
    Rennes, 35000, France
    Recruiting
  • Private psychiatric practice
    Saint-Grégoire, 35760, France
    Recruiting
  • Private psychiatric practice
    Saint-Nazaire, 44600, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Feb 2027, 22 months after the start.

Of 40 industry-sponsored interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 36. This study's planned 22 months is above that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2024
First posted
Sep 19, 2024
StartActual
Mar 5, 2025
Primary completionEst.
Feb 4, 2027
CompletionEst.
Feb 4, 2027
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06601140
Lead sponsor
Emobot
Collaborators
Nantes University Hospital, Private psychiatric practice, Saint-Nazaire, Groupement Hospitalier Paul Guiraud, Villejuif, Centre Hospitalier Guillaume Régnier, RENNES, Centre de Psychothérapie Nancéen, Laxou, Rumb, Private psychiatric pratice, Agen, Private psychiatric pratice, Caen
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Mar 5, 2025
Primary completion
Feb 4, 2027 (estimated)
Completion
Feb 4, 2027 (estimated)
Last update
Feb 19, 2026

Study contacts

Tanel PETELOT
Contact
tanel.petelot@emobot.fr
+33 6 51 44 26 67

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion